{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:28:44Z","timestamp":1786325324472,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277109"],"award-info":[{"award-number":["22277109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117154","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:56:38Z","timestamp":1784721398000},"page":"117154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel peptide-MHC-based T cell engager synergizes with tumor-targeted IL-12 for immunotherapy of solid tumors"],"prefix":"10.1016","volume":"186","author":[{"given":"Shihui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2026.117154_bb0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.117154_bb0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117154_bb0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.117154_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.intimp.2026.117154_bb0025","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.117154_bb0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117154_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunother. Adv."},{"issue":"2","key":"10.1016\/j.intimp.2026.117154_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.117154_bb0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.117154_bb0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.117154_bb0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2026.117154_bb0060","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer\u2013Then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117154_bb0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the Interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2026.117154_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.intimp.2026.117154_bb0075","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.117154_bb0080","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1078-0432.CCR-18-0381","article-title":"Revisiting Interleukin-12 as a Cancer immunotherapy agent","volume":"24","author":"Berraondo","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117154_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/bies.70086","article-title":"IL-12 and the antitumor response: the good, the bad, and the unknown","volume":"48","author":"Fesneau","year":"2026","journal-title":"Bioessays"},{"key":"10.1016\/j.intimp.2026.117154_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100053","article-title":"The multifaceted role of IL-12 in cancer","volume":"5","author":"Habiba","year":"2022","journal-title":"Adv. Cancer Biol. Metastasis"},{"issue":"5","key":"10.1016\/j.intimp.2026.117154_bb0095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.intimp.2026.117154_bb0100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"67","key":"10.1016\/j.intimp.2026.117154_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117154_bb0110","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.addr.2013.05.013","article-title":"Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant","volume":"65","author":"Hafner","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2026.117154_bb0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG oligonucleotides as vaccine adjuvants","volume":"2197","author":"Kayraklioglu","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117154_bb0120","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2326-6066.CIR-15-0037","article-title":"Committing cytomegalovirus-specific CD8 T cells to eliminate tumor cells by bifunctional major histocompatibility class I antibody fusion molecules","volume":"3","author":"Schmittnaegel","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117154_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2395499","article-title":"IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release","volume":"16","author":"Schardt","year":"2024","journal-title":"MAbs"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:40:57Z","timestamp":1786322457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S1567576926010003"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117154","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel peptide-MHC-based T cell engager synergizes with tumor-targeted IL-12 for immunotherapy of solid tumors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117154"}}